Aspire Biopharma Positive Top-Line in Trial of Sublingual Aspirin for Suspected Heart Attack

 

• According to the NIH, Acute myocardial infarction (AMI) is a major cause of death, affecting nearly 3 million Americans each year and resulting in over a million deaths

• Trial demonstrates dramatically higher and more rapid therapeutic impact compared to standard chewed aspirin tablets in clinical trial

• Aspire's sublingual aspirin was safe and well-tolerated

• Aspire plans to review clinical trial results with the FDA to enable a potential regulatory submission for accelerated approval

• https://www.morningstar.com/news/accesswire/1061839msn/aspire-biopharma-announces-positive-top-line-results-from-clinical-trial-of-investigational-new-sublingual-aspirin-product-for-treatment-of-suspected-acute-myocardial-infarction-heart-attack